The alternatives
Hims & Hers scores 85/100 (grade B, ranked #27) on The Verdict Score. Here are the top-rated GLP-1 providers we'd weigh against it — same six-factor rubric, and no score is adjusted for payment.
Hims & Hers — FDA warning letter, September 2025. Addressed to Hims & Hers Health, Inc. dba Hims, and public in FDA’s warning-letter database.
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
CoreAge Rx scores 94/100 to Hims & Hers's 85, and our Hims & Hers vs CoreAge Rx ruling sets the two out factor by factor.
A medication-access veteran turned GLP-1 provider — LegitScript-verified and nationwide, if middle-priced.
NiceRx matches Hims & Hers at 85/100; our NiceRx ruling in full has the pricing conditions and the caveats in detail.
Six programs across four terms on one public page, four dispensing pharmacies named with addresses, and a no-intro-rate commitment the arithmetic actually supports.
No BS RX matches Hims & Hers at 85/100; our No BS RX ruling in full has the pricing conditions and the caveats in detail.
Low, honest pricing on both molecules from a LegitScript-verified nationwide operator.
Gimme Care matches Hims & Hers at 85/100; our full write-up on Gimme Care has the pricing conditions and the caveats in detail.
One of the few programs whose headline is the actual monthly rate, with the prescribing physician and the dispensing pharmacy both named.
Renlo Health matches Hims & Hers at 85/100; our Renlo Health ruling in full has the pricing conditions and the caveats in detail.
The cheapest flat, month-to-month tirzepatide in the ranking at $125 — every figure below it carries a starting-dose, microdose or prepay condition — with semaglutide to match, but a missing LegitScript listing keeps it out of the trust tier.
Trimi Health scores 83/100 to Hims & Hers's 85; our full write-up on Trimi Health has the pricing conditions and the caveats in detail.
One of the rare programs offering an oral/sublingual route on both molecules with all-inclusive pricing — marked down hard because the numbers are company-stated rather than independently verified, and the company carries an FDA warning letter from September 2025.
Direct Meds scores 82/100 to Hims & Hers's 85; the full Direct Meds review has the pricing conditions and the caveats in detail.
See the complete rankings or head to the comparison hub.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Not medical advice; see our disclosure.